Defence Therapeutics Inc. Defence Therapeutics Inc.

Defence Therapeutics Inc.

DTC

Rank in Stocks #29270
Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a... Headquartered in Vancouver, Canada, Defence Therapeutics Inc. is a biotechnology company founded in 2017. This firm focuses on pioneering biological and biosimilar therapeutic solutions for both cancer and infectious diseases. A cornerstone of its approach is the exclusive ACCUM™ technology, engineered to precisely and safely transport vaccine antigens or antibody-drug conjugates (ADCs) directly to their intended cellular targets. The company's development efforts span several key areas: novel dendritic cell vaccines for various cancers, protein-based vaccines addressing COVID-19 and other infectious ailments, and specialized antibody-drug conjugate products aimed at different cancer types. Defence Therapeutics Inc. adopted its current name in March 2020, having previously operated as Accum Therapeutics Inc.
Share Price
$0.27889602
Last synced: 2026-10-19
Market Cap
$21.14M
Change (1 day)
11.76%
Change (1 year)
-52.35%
Country
CA
Trade Defence Therapeutics Inc. (DTC)

Category

Healthcare
Number of shares outstanding for Defence Therapeutics Inc. (DTC)
Number of shares outstanding as of October 2026: 0
According to Defence Therapeutics Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of October 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Defence Therapeutics Inc. (DTC) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
253.90M -
US
396.00M -
US
478.91M -
AU
- -
CH
62.19M -
NL